- idUS
- Listar por autor
Listar por autor "Long, Georgina V."
Mostrando ítems 1-3 de 3
-
Artículo
Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Khattak, Muhammad A.; Luke, Jason J.; Long, Georgina V.; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Dirk; Cruz Merino, Luis de la; Kirkwood, John M. (Elsevier Science Ltd, 2022)Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in ...
-
Artículo
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Weber, Jeffrey S.; Schadendorf, Dirk; Del Vecchio, Michele; Larkin, James; Atkinson, Victoria; Schenker, Michael; Cruz Merino, Luis de la; Long, Georgina V. (American Society of Clinical Oncology, 2023)PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate ...
-
Artículo
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Schadendorf, Dirk; Luke, Jason John; Ascierto, Paolo A.; Long, Georgina V.; Rutkowski, Piotr; Khattak, Adnan; Cruz Merino, Luis de la; Scolyer, Richard A. (BMC, 2024)Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival ...